Zacks Investment Research
27 Nov 2025, 15:55 UTC · 48w ago
Impact · against what's priced in
CareDx shows positive momentum driven by upward earnings revisions and a consensus price target suggesting 28% upside. These technical and analyst-driven signals provide a bullish outlook for the stock's short-term trajectory.
No priced-in read yet
What the story claims
2 claims · scored −1 bearish … +1 bullish
Analysts are revising earnings estimates for CareDx (CDNA) upward.
More positive than 75% of claims this week
The mean analyst price target for CDNA is $22.80, representing a potential 28% upside from its last close of $17.81.
So whatA significant gap between current price and consensus targets can attract buyers, though the text notes the variability of such targets.
Continue reading
5 related stories
Analysts are revising earnings estimates upward and maintaining a mean price target of $22.80, implying a 28% upside from the current price of $17.81.
Read from the article alone
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 61% of claims this week
Which stocks this story touches
More positive than 71% of ticker scores this week
The stock has gained 24.7% over four weeks and analysts suggest a 28% upside potential with positive earnings estimate revisions.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
3h ago
+396.7%
Price agrees with the score
$88.47 vs $17.81 close before publication (Nov 26) · not market-adjusted
CDNA chart →
